Abstract
Lipid metabolism disorders and inflammation response play important roles in the pathogenesis of coronary heart disease (CHD). Danqi Pill (DQP) is prescribed routinely in the treatment of CHD. DQP has both anti-inflammatory and lipid-lowering effects. However, its pharmacological mechanisms are not
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
